, European Hospital
, Oncohematological Geriatric Unit. Hôpital Charles-Foix
, Internal Medicine Research and Care Unit, European Hospital
Phone : (33) 628 325 242 Fax : (33) 413 427 712. E-mail : frederique.retornaz@gmail.com REFERENCES: 1. Inca. Épidémiologie des cancers chez les patients de 65 ans et plus, 2019. ,
Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge, Rev Med Suisse, vol.5, pp.1116-1123, 2009. ,
,
, A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients, New England Journal of Medicine, vol.345, issue.15, pp.1091-1098, 2001.
Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer, Expert Rev Gastroenterol Hepatol, vol.10, issue.12, pp.1321-1361, 2016. ,
Détection et évaluation de la dénutrition en oncologie : quels sont les outils, pour quel type de cancer et dans quels buts, Bulletin du Cancer, vol.103, issue.9, pp.776-85, 2016. ,
A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer, Journal of Geriatric Oncology, vol.9, issue.1, pp.74-80, 2018. ,
Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper, Journal of Geriatric Oncology, vol.9, issue.4, pp.382-92, 2018. ,
Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy, Medicine (Baltimore), issue.48, p.97, 2018. ,
La sarcopénie : un concept d'importance croissante dans la prise en charge du cancer colorectal. La Presse Médicale, vol.43, pp.628-660, 2014. ,
The prevalence and outcomes of frailty in older cancer patients: a systematic review, Annals of Oncology, vol.26, issue.6, pp.1091-101, 2015. ,
Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study, vol.11, p.149732, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482501
Use of comprehensive geriatric assessment in older cancer patients: Contents, Critical Reviews in Oncology/Hematology, p.p, 2005. ,
,
, Chemotherapy-Related Hospitalization Among Community Cancer Center Patients. Oncologist, vol.16, issue.3, pp.378-87, 2011.
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer, Breast Cancer Res Treat, vol.117, issue.1, 2009. ,
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy, Eur J Cancer ,
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly, J Clin Oncol, vol.24, issue.15, pp.2368-75, 2006. ,
,
The Value of Geriatric Assessments in Predicting Treatment Tolerance and All-Cause Mortality in Older Patients With Cancer. The Oncologist, vol.17, pp.1439-1488, 2012. ,
Geriatric Factors analysis from FFCD ,
, Phase III Study of First-Line Chemotherapy for elderly Metastatic Colorectal Cancer Patients
, Eur J Cancer, vol.74, pp.98-108, 2017.
The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people, British Journal of Cancer, vol.112, issue.9, pp.1435-1479, 2015. ,
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients, Critical Reviews in Oncology/Hematology, vol.79, issue.3, pp.302-309, 2011. ,
Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.63, pp.724-754, 2008. ,
Frailty in Older Adults: Evidence for a Phenotype, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.56, issue.3, pp.146-57, 2001. ,
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study, The Journals of Gerontology: Series A, vol.63, issue.5, pp.138-187, 2008. ,
Predicting Chemotherapy Toxicity and Death in Older Adults With Colon Cancer: Results of MOST Study, 2018. ,
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012. ,
Predicting early death in older adults with cancer, Eur J Cancer, vol.100, pp.65-74, 2018. ,
Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living, J Am Geriatr Soc, vol.31, issue.12, pp.721-728, 1983. ,
The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire, J Gerontol, vol.36, issue.4, pp.428-462, 1981. ,
Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version, Clinical Gerontologist: The Journal of Aging and Mental Health, vol.5, issue.1-2, pp.165-73, 1986. ,
Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample, J Am Geriatr Soc, vol.53, issue.5, pp.871-875, 2005. ,
Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test, Arch Clin Neuropsychol, vol.11, issue.6, pp.529-568, 1996. ,
Use of BMI in the assessment of undernutrition in older subjects: reflecting on practice, Proc Nutr Soc, vol.64, issue.3, pp.313-320, 2005. ,
Comparison of the health and functional status between older inpatients with and without cancer admitted to a geriatric/internal medicine unit, J Gerontol A Biol Sci Med Sci, vol.62, issue.8, pp.917-939, 2007. ,
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial, Ann Oncol, vol.24, issue.11, pp.2808-2821, 2013. ,
Reliability and validity of questions about exercise in the Canadian Study of Health and Aging, Int Psychogeriatr, vol.13, issue.1, pp.177-82, 2001. ,
Up & Go": a test of basic functional mobility for frail elderly persons, J Am Geriatr Soc, vol.39, issue.2, pp.142-150, 1991. ,
,
Phenotype of Frailty: Characterization in the Women's Health and Aging Studies, J Gerontol A Biol Sci Med Sci, vol.61, issue.3, pp.262-268, 2006. ,
Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study, Annals of oncology : official journal of the European Society for Medical Oncology, vol.24, issue.5, pp.1306-1318, 2013. ,
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, pp.3457-65, 2011. ,
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012. ,
How and why to perform a geriatric assessment in clinical practice, Annals of Oncology, vol.19, pp.300-303, 2008. ,
Analysis of treatment practices for elderly cancer patients in, J Clin Oncol, vol.23, issue.16, pp.3802-3810, 2005. ,
Prostate Cancer in the Elderly Patient, J Clin Oncol, vol.32, issue.24, pp.2523-2530, 2014. ,
Implementing Frailty Into Clinical Practice: A Cautionary Tale, J Gerontol A Biol Sci Med Sci, vol.68, issue.12, pp.1505-1516, 2013. ,
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012. ,
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, Journal of Clinical Oncology, vol.29, issue.25, pp.3457-65, 2011. ,
Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive ,
Use of Références Bibliographie : 1. Inca -L'essentiel des faits et chiffres des cancers en France, 2019. ,
, Inca -Épidémiologie des cancers chez les patients de 65 ans et plus -Oncogériatrie, 2019.
Patients et proches -Les cancers du côlon -Quelques chiffres, 2017. ,
Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge ? ,
, , 2009.
Does a ,
, Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?, J Gerontol A Biol Sci Med Sci, vol.63, issue.7, pp.724-754, 2008.
Cancer in the elderly: why so badly treated? Lancet Lond Engl, vol.335, pp.1020-1022, 1990. ,
, Use of comprehensive geriatric assessment in older cancer patients: Contents, Critical Reviews in Oncology/Hematology, p.p, 2005.
A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit Rev Oncol Hematol, vol.49, issue.1, pp.69-75, 2004. ,
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients, Crit Rev Oncol Hematol, vol.79, issue.3, pp.302-309, 2011. ,
,
, Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J Clin Oncol, vol.29, issue.27, pp.3636-3678, 2011.
Comprehensive Geriatric Assessment for Older Patients With Cancer, J Clin Oncol, vol.25, issue.14, pp.1824-1855, 2007. ,
Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study, J Clin Oncol, vol.20, issue.2, pp.494-502, 2002. ,
How and why to perform a geriatric assessment in clinical practice ,
, Oncol, vol.19, pp.300-303, 2008.
Analysis of treatment practices for elderly cancer patients in, Holowaty E Straus Siu LL, 2005. ,
Use of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review, JNCI J Natl Cancer Inst, vol.16, issue.15, pp.1134-64, 2012. ,
, Hépato-gastro-entérologie -Chirurgie digestive, 4e édition, sous l'égide de la Collégiale des Universitaires en Hépato-gastro-entérologie. ©2018
, © Cancers colorectaux /du diagnostic au suivi, INCa, septembre 2018
,
, Prédisposition héréditaire aux cancers du côlon, du rectum et de l'utérus, Pathol Biol, 2006.
, E-cancer. Cancers colorectaux -Les tumeurs du côlon, HAS. Cancer colorectal. Février, vol.54, issue.4, pp.215-244, 2008.
, A genetic model for colorectal tumorigenesis, Fearon ER, 1990.
Colorectal cancer carcinogenesis: a review of mechanisms, Cancer Biol Med, vol.13, issue.1, pp.120-155, 2016. ,
Molecular biology of colorectal cancer, Curr Probl Cancer, vol.21, issue.5, pp.233-99, 1997. ,
CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci, vol.96, issue.15, pp.8681-8687, 1999. ,
, Cancers du colon et du rectum, pp.10-2017, 2019.
,
, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors. Rev DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.
Etiologic insights from surface adjustment of colorectal carcinoma incidences: an analysis of the U.S. SEER data, Am J Gastroenterol, 2000. ,
, TNM Classification of malignant tumours
, , 2017.
Are 12 nodes needed to accurately stage T1 and T2 colon cancers?, Dig Dis Sci, vol.54, issue.3, pp.640-647, 2009. ,
Assessing the adequacy of lymph node yield for ,
Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer, J Clin Oncol, vol.27, issue.36, pp.6166-71, 2009. ,
org -Cancer colorectal métastatique, p.75 ,
, Ligue contre le cancer. Cancers colon rectum-Octobre2017, 2019.
,
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.10, pp.1638-1682, 2010. ,
,
,
, Thésaurus National de Cancérologie Digestive, 2019.
org -Société savante médicale française d'hépato-gastroentérologie et ,
,
, Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial, Lancet Oncol, 2010.
,
L'association 5FU/mitomycine C dans le traitement du cancer colorectal métastatique lourdement pré-traité apporte-t-elle un bénéfice ? Résultats d'une étude multicentrique ,
,
, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and metaanalysis of individual patient data, Lancet Oncol, vol.16, issue.16, pp.1639-50, 2015.
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Mol Cancer Ther, vol.5, issue.11, pp.2895-904, 2006. ,
,
, Population study of dihydropyrimidine dehydrogenase in cancer-patients, 1994.
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) ,
, JNCI J Natl Cancer Inst, vol.106, issue.12, 2014.
, Prevention of 5-FU-induced toxicities using pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach, J Clin Oncol, vol.31, pp.351-351, 2013.
, INCa et HAS -Recherche d'un deficit en dihydropyrimidine deshydrogenase visant a prevenir certaines toxicites severes-décembre, 2018.
, Common Terminology Criteria for Adverse Events (CTCAE), p.147, 2017.
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management, Cancer, vol.100, issue.9, pp.1993-1997, 2004. ,
Pharmacology of cancer chemotherapy in the older person ,
, Clin Geriatr Med, vol.13, issue.1, pp.169-83, 1997.
Tolerability, dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer in the elderly. A North Central Cancer Treatment Group Study, Proc Am Soc Clin Oncol, vol.384, 2001. ,
,
, Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and 106
, fluorouracil bolus plus continuous infusion, Anticancer Res, vol.21, issue.1A, pp.489-92, 2001.
,
, Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie une discipline en devenir. Rev Médecine Interne, vol.26, pp.216-241, 2005.
Hematopoietic growth factors in the older cancer patient, Curr Opin Hematol, vol.8, issue.3, pp.170-87, 2001. ,
Tolerance to Chemotherapy in Elderly Patients with Cancer. Cancer Control, vol.14, pp.44-56, 2007. ,
Improving medication use for older adults: an integrated research agenda, Ann Intern Med, vol.139, issue.5, pp.425-434, 2003. ,
, Résumé des Caractéristiques du Produit : Irinotecan [Internet, 2019.
Prise en charge des cancers colorectaux des sujets âgés, Gastroentérologie Clin Biol, vol.29, issue.10, pp.1014-1037, 2005. ,
,
, Influence of sex and age on fluorouracil clearance, J Clin Oncol, vol.10, issue.7, pp.1171-1176, 1992.
,
, Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer, J Clin Oncol, 2006.
,
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, issue.19, pp.3992-4000, 2002. ,
Predictors of tolerance to chemotherapy in older cancer patients, Eur J Cancer, vol.38, issue.11, pp.1466-73, 2002. ,
Joint NCI-EORTC consensus meeting on neoplasia in the elderly, Eur J Cancer Oxf Engl, pp.15-16, 1990. ,
Age and ,
URL : https://hal.archives-ouvertes.fr/hal-01382787
Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer ,
, Anticancer Res, vol.18, issue.1B, pp.517-538, 1998.
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy, Cancer Chemother Pharmacol, vol.42, issue.4, pp.336-376, 1998. ,
,
, A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
, N Engl J Med, vol.345, issue.15, pp.1091-1098, 2001.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer ,
, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, issue.16, pp.2938-2985, 2000.
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study, Cancer Chemother Pharmacol, 2008. ,
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.13, pp.3104-3115, 2005. ,
Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, vol.352, issue.26, pp.2696-704, 2005. ,
, Etat des lieux et perspectives en oncogériatrie, 2009.
Phase II trial of prolonged infusion gemcitabine (Gemzar) in advanced colorectal carcinoma : in vivo proof of a pharmacologic principle, Ann Oncol, vol.9, issue.2, p.156, 1998. ,
Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF), vol.24, pp.372-83, 2003. ,
Addition of Bevacizumab to ,
, Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials, J Clin Oncol, vol.27, issue.2, pp.199-205, 2009.
Ten Bokkel Huinink D. Multidisciplinary decision-making on chemotherapy for colorectal cancer: an agebased comparison, J Geriatr Oncol, vol.6, issue.3, pp.225-257, 2015. ,
Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in 109 population-based studies?, Eur J Cancer Oxf Engl, vol.49, issue.13, pp.2919-2944, 1990. ,
,
, Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment, Clin Interv Aging, 1645.
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study, Critical Reviews in Oncology/Hematology, vol.82, issue.11, pp.241-252, 1998. ,
Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?, Eur J Cancer, vol.46, issue.6, pp.1019-1044, 2010. ,
,
,
, Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, pp.3457-65, 2011.
,
, Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation, J Clin Oncol, vol.28, issue.15_suppl, pp.9000-9000, 2010.
,
, Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology, J Clin Oncol, 2018.
L'évaluation gériatrique et les scores pronostiques chez le patient âgé atteint de cancer : une aide à la décision thérapeutique ?, Bull Cancer, vol.104, issue.11, pp.946-55, 2017. ,
Up & Go": a test of basic functional mobility for frail elderly persons, J Am Geriatr Soc, vol.39, issue.2, pp.142-150, 1991. ,
Gait Speed and Survival in Older Adults, JAMA, vol.305, issue.1, pp.50-58, 2011. ,
Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living, J Am Geriatr Soc, vol.31, issue.12, pp.721-728, 1983. ,
The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire, J Gerontol, vol.36, issue.4, pp.428-462, 1981. ,
Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 1982. ,
Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975. ,
Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample, J Am Geriatr Soc, vol.53, issue.5, pp.871-875, 2005. ,
,
, MoCA: a brief screening tool for mild cognitive impairment, The Montreal Cognitive Assessment, vol.53, issue.4, pp.695-704, 2005.
,
, Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test, Arch Clin Neuropsychol Off J Natl Acad Neuropsychol, vol.11, issue.6, pp.529-568, 1996.
Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version, Clin Gerontol J Aging Ment Health, vol.5, issue.1-2, pp.165-73, 1986. ,
The hospital anxiety and depression scale, Acta Psychiatr Scand, vol.67, issue.6, pp.361-70, 1983. ,
Comparison of the health and functional status between older inpatients with and without cancer admitted to a geriatric/internal medicine unit, J Gerontol A Biol Sci Med Sci, vol.62, issue.8, pp.917-939, 2007. ,
A manual of guidelines for scoring the cumulative illness rating scale for geriatrics, Pittsbg Pa Univ Pittsburgh, 1991. ,
Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries, Am J Epidemiol, vol.173, issue.6, pp.676-82, 2011. ,
THE MINI NUTRITIONAL ASSESSMENT (MNA®) REVIEW OF THE LITERATURE -WHAT DOES IT TELL US?, J Nutr, vol.10, issue.6, p.23, 2006. ,
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial, Ann Oncol Off J Eur Soc Med Oncol, 2013. ,
Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients, vol.10, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-02088193
,
, Chemotherapy-Related Hospitalization Among Community Cancer Center Patients. The Oncologist, vol.16, pp.378-87, 2011.
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer, Breast Cancer Res Treat, vol.117, issue.1, 2009. ,
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy, Eur J Cancer Oxf Engl, vol.46, issue.12, pp.2225-2259, 1990. ,
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, issue.15, pp.2368-75, 2006. ,
Older Breast Cancer Survivors: Geriatric Assessment Domains Are Associated With Poor Tolerance of Treatment Adverse Effects and Predict Mortality Over 7 Years of Follow-Up, J Clin Oncol, vol.28, issue.3, pp.380-386, 2010. ,
, Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly, Acta Oncologica, vol.55, issue.1, 2019.
Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study, Ann Oncol Off J Eur Soc Med Oncol, vol.24, issue.5, pp.1306-1318, 2013. ,
The influence of clinical assessment (including age) and geriatric assessment on treatment decisions 113 in older patients with cancer, J Geriatr Oncol, vol.4, issue.3, pp.235-276, 2013. ,
, J Colorectal Dis, vol.32, issue.11, pp.1625-1634, 2017.
La fragilité : en quête d'un nouveau paradigme clinique et de recherche pertinent, Rev Médecine Interne, vol.30, issue.2, pp.105-114, 2009. ,
Qu'est-ce que la fragilité en oncogériatrie ? Oncologie, vol.13, pp.73-80, 2011. ,
Transitions between frailty states among community-living older persons, Arch Intern Med, vol.166, issue.4, pp.418-441, 2006. ,
Models, Definitions, and Criteria for Frailty ,
, Conn's Handbook of Models for Human Aging
How to select a frail elderly population? A comparison of three working definitions, J Clin Epidemiol, 1999. ,
Antecedents of frailty over three decades in an older cohort, J Gerontol B Psychol Sci Soc Sci, vol.53, issue.1, pp.9-16, 1998. ,
,
Inactivity and weight loss: effective criteria to identify frailty, J Nutr Health Aging, vol.7, issue.1, pp.55-60, 2003. ,
, Disability and frailty among elderly Canadians: a comparison of six surveys, Int Psychogeriatr, vol.13, issue.1, pp.159-67, 2001.
Frailty in Older Adults: Evidence for a Phenotype, J Gerontol A Biol Sci Med Sci, vol.56, issue.3, pp.146-57, 2001. ,
New Dynamics of Ageing (NDA) Preparatory Network. A life course approach to healthy aging, frailty, and capability, J Gerontol A Biol Sci Med Sci, vol.62, issue.7, pp.717-738, 2007. ,
A global clinical measure of fitness and frailty in elderly people, CMAJ Can Med Assoc J, 2005. ,
, Aug, vol.30, issue.5, pp.489-95
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women, Arch Intern Med, vol.168, issue.4, pp.382-391, 2008. ,
Usefulness of Frailty Markers in the Assessment of the Health and Functional Status of Older Cancer Patients Referred for Chemotherapy: A Pilot Study, J Gerontol Ser A, vol.63, issue.5, pp.518-540, 2008. ,
Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study, vol.11, p.149732, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482501
The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the Community ,
, J Am Geriatr Soc, vol.49, issue.12, pp.1691-1700, 2001.
Higher Vulnerable Elders Survey Scores Predict Death and Functional Decline in Vulnerable Older People, J Am Geriatr Soc, vol.54, issue.3, pp.507-518, 2006. ,
What would make a definition of frailty successful? Age Ageing, 2005. ,
Something About Frailty, J Gerontol A Biol Sci Med Sci, vol.57, issue.11, pp.698-704, 2002. ,
,
, Développement d'un cadre de travail pour comprendre et étudier la fragilité, Gerontol Soc, vol.27, issue.2, pp.15-29, 2004.
Frailty: An Emerging Research and Clinical Paradigm--Issues and Controversies, J Gerontol A Biol Sci Med Sci, vol.62, issue.7, pp.731-738, 2007. ,
Static and dynamic measures of frailty predicted decline in performance-based and self-reported physical functioning, J Clin Epidemiol, vol.58, issue.11, pp.1188-98, 2005. ,
Le sujet âgé fragile. La Revue de Gériatrie, vol.27, pp.569-581 ,
Le concept de fragilité : pourquoi est-il essentiel ? La Revue de Gériatrie, vol.25, pp.135-138, 2000. ,
A rational approach to nutritional assessment, Clin Nutr ,
Evidence-based nutritional support of the elderly cancer patient, Nutrition ,
Nutrition chez le patient adulte atteint de cancer : quand et comment évaluer l'état nutritionnel d'un malade atteint de cancer ? Comment faire le diagnostic de dénutrition et le diagnostic de dénutrition sévère chez un malade atteint de cancer ? Quelles sont les situations les plus à risque de dénutrition ?, Nutr Clin Métabolisme, 2012. ,
Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, 2011. ,
Détection et évaluation de la dénutrition en oncologie : quels sont les outils, pour quel type de cancer et dans quels buts, Bull Cancer, vol.103, issue.9, pp.776-85, 2016. ,
ESPEN expert group recommendations for action against cancer-related malnutrition, Clin Nutr, 2017. ,
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres ,
, Br J Cancer, vol.102, issue.6, pp.966-71, 2010.
A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer, J Geriatr Oncol, vol.9, issue.1, pp.74-80, 2018. ,
What We Have Learned about Cachexia in Gastrointestinal Cancer, Dig Dis, vol.21, issue.3, pp.198-213, 2003. ,
Impact of nutrition on pharmacokinetics of antineoplastic agents, p.4 ,
Pharmacokinetics of methotrexate in adult Indian patients and its relationship to nutritional status, Cancer Treat Rep ,
No effect of dose, hepatic function ,
, Br J Cancer, vol.66, issue.4, pp.668-72, 1992.
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998. ,
, Clinical Guidelines. J Parenter Enter Nutr, vol.37, issue.1, pp.23-36, 2013.
Nutrition en oncogériatrie. Cancer/Radiothérapie, vol.13, pp.628-659, 2009. ,
, , 2018.
Total parenteral nutrition in cancer patients: why and when?, Nutr Clin Care Off Publ Tufts Univ, vol.8, issue.2, pp.89-92, 2005. ,
Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced nonsmall cell lung cancer patients with poor performance status. BMC Cancer, vol.17, p.6, 2017. ,
, European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People, vol.39, pp.412-435, 2010.
Sarcopenia: Definition, Epidemiology, and Pathophysiology, J Bone Metab, vol.20, issue.1, p.1, 2013. ,
Rev Médecine Interne, vol.30, 2009. ,
Loss of skeletal muscle mass in aging: Examining the relationship of starvation, sarcopenia and cachexia ,
Role of IL-6 In Cachexia -Therapeutic Implications, Curr Opin Support Palliat Care, vol.8, issue.4, pp.321-328, 2014. ,
Beyond TGF?: roles of other TGF? superfamily members in cancer, Nat Rev Cancer, vol.13, issue.5, pp.328-369, 2013. ,
Overexpression of activin A in stage IV colorectal cancer, Gut, vol.49, issue.3, pp.409-426, 2001. ,
, Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease | Elsevier Enhanced Reader, 2019.
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? Pharmacol Ther, vol.196, pp.135-59, 2019. ,
Short Physical Performance Battery, Usual Gait Speed, Grip Strength and Vulnerable Elders Survey Each Predict Functional Decline among Older Women with Breast Cancer, J Geriatr Oncol, 2017. ,
Handgrip fatiguing exercise can provide objective assessment of cancer-related fatigue: a pilot study ,
, Support Care Cancer, vol.27, pp.229-267, 2019.
Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer, vol.21, pp.3261-70, 2013. ,
Low skeletal muscle is associated with toxicity in patients included in phase I trials, Invest New Drugs, 2014. ,
, Apr, vol.32, issue.2, pp.382-389
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines ,
, Oncotarget, vol.9, issue.39, 2018.
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens, Cancer Med, vol.5, issue.4, pp.607-623, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01881582
Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer, Nutr Cancer ,
,
, Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity. Clin Cancer Res, vol.13, pp.3264-3272, 2007.
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer ,
, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012.
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study, Crit Rev Oncol Hematol, 2011. ,
Developing a cancer-specific geriatric assessment, Cancer, vol.104, issue.9, 1998. ,
Transitions Between Frailty States Among Community-Living Older Persons, Arch Intern Med, vol.166, issue.4, pp.418-441, 2006. ,
,
Predicting Chemotherapy Toxicity and Death in Older Adults With Colon Cancer: Results of MOST Study, Am Soc Clin Oncol Chic, 2018. ,
,
, Predicting early death in older adults with cancer, Eur J Cancer, vol.100, pp.65-74, 2018.
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012. ,
Implementing Frailty Into Clinical Practice: A Cautionary Tale, J Gerontol Ser A ,
,
Breast cancer treatment guidelines in older women, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.4, pp.783-91, 2005. ,
Determinants of Survival in Older Cancer Patients ,
, JNCI J Natl Cancer Inst, vol.88, issue.15, pp.1031-1039, 1996.
,
, Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women, J Clin Oncol, vol.21, pp.3580-3587, 2003.
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol, 2016. ,
, Jul, vol.10, issue.20, pp.2366-71
Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial, Oncology, vol.69, issue.5, pp.384-90, 2005. ,
,
, Br J Cancer, vol.91, issue.8, pp.1453-1461, 2004.
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, N Engl J Med, vol.341, issue.27, pp.2061-2068, 1999. ,
,
Evaluation of Clinical Pharmacy Services in a ,
, Hematology/Oncology Outpatient Setting. Ann Pharmacother, vol.40, issue.9, pp.1527-1560, 2006.
Pharmaceutical validation as a process of improving the quality of antineoplastic treatment, J Oncol Pharm Pract, vol.11, issue.2, pp.45-50, 2005. ,
Early discontinuation but not the timing of adjuvant therapy affects survival of patients with highrisk colorectal cancer: a population-based study, Dis Colon Rectum, vol.53, issue.10, pp.1432-1440, 2010. ,
The frailty syndrome: a critical issue in geriatric oncology, Crit Rev Oncol Hematol, 2003. ,
, Rôle du facteur tissulaire dans les métastases hépatiques du cancer colo-rectal : vers une nouvelle cible thérapeutique? -PDF [Internet, 2019.
, Cancer colorectal métastatique, vol.4
, +/-bévacizumab 5 mg/kg (Avastin®) avec schéma de 5FU modifié (recommandation : grade B)
Xeloda®) (recommandation : grade A) ,
, 5mg/kg (recommandation : gradeB), vol.7
, ? FOLFIRI (irinotécan 180 mg/m 2 -LV5FU2 simplifié) (recommandation : grade A)
, bévacizumab 5mg/kg (recommandation : gradeB)
, puis 250mg/m 2 hebdomadaire si statut tumoral RAS non muté (recommandation : grade B). Possibilité d'administrer une double dose (500 mg/m 2 ) toutes les deux semaines (recommandation : grade B)
, mg/kg si le statut tumoral RAS est non muté (recommandation : grade C)
, ? FOLFOX 4 simplifié (oxaliplatine 85 mg/m2-LV5FU2 simplifié) (recommandation : grade A)
, +/-bévacizumab 5 mg/kg (recommandation : grade B)
, mg/kg si le statut tumoral RAS est non muté (recommandation : grade B)
, 400 mg/m2 puis 250 mg/m 2 hebdomadaire si statut tumoral RAS non muté. Possibilité d'administrer une double dose (500 mg/m 2 ) toutes les deux semaines (recommandation : grade C)
irinotécan 165 mg/m 2 -oxaliplatine 85 mg/m 2 -Ac Folinique 200 ,
, ? FOLFOX 7 (oxaliplatine 130mg/m2 -LV5FU2 simplifié sans 5FU bolus) 6 cures puis LV5FU2 simplifié puis réintroduction de l'oxaliplatine à la progression (stratégie OPTIMOX 1) (recommandation : grade B)
, recommandation : grade A) +/-bévacizumab 7,5 mg/kg (recommandation : grade B)
The mini-cog: a cognitive "vitals signs" measure for dementia screening in multi-lingual elderly, Items 1. Etes-vous satisfait(e) de votre vie? Oui Non*, vol.15, p.1021, 2000. ,
, Avez-vous renoncé à un grand nombre de vos activités? Oui* Non
, Avez-vous l'impression que votre vie est vide? Oui* Non
, Vous ennuyez-vous souvent? Oui* Non
, Envisagez-vous l'avenir avec optimisme? Oui Non*
, Etes-vous souvent préoccupé(e) par des pensées qui reviennent sans cesse? Oui* Non
, Etes-vous de bonne humeur la plupart du temps? Oui Non*
, Craignez-vous un mauvais présage pour l'avenir? Oui* Non
, Etes-vous heureux(se) la plupart du temps Oui Non*
, Vous sentez-vous souvent nerveux(se) au point de ne pouvoir tenir en place? Oui* Non 12. Préférez-vous rester seul(e) dans votre chambre plutôt que d'en sortir Oui* Non, Avez-vous souvent besoin d'aide? Oui* Non 11
, Pensez-vous que votre mémoire est plus mauvaise que celle de la plupart des gens? Oui* Non, L'avenir vous inquiète-t-il? Oui* Non, vol.14
, Pensez-vous qu'il est merveilleux de vivre à notre époque? Oui Non*
,
, Avez-vous le sentiment d'être désormais inutile? Oui* Non
, Oui* Non 19. Trouvez-vous que la vie est passionnante? Oui Non*
, Avez-vous des difficultés à entreprendre de nouveaux projets? Oui* Non
, Désespérez-vous de votre situation présente? Oui* Non 23. Pensez-vous que la situation des autres est meilleure que la votre Oui* Non 24. Etes-vous souvent irrité(e) par des détails? Oui* Non 25. Eprouvez-vous souvent le besoin de pleurer, Avez-vous beaucoup d'énergie? Oui Non* 22
, Etes-vous content(e) de vous lever le matin? Oui Non* 28. Refusez-vous souvent les activités proposées? Oui* Non 29. Vous est-il facile de prendre des décisions, Avez-vous du mal à vous concentrer? Oui* Non 27
, Avez-vous l'esprit aussi clair qu'autrefois? Oui Non*
, Aucun problème: Aucune pathologie n'affecte ce système ou problèmes médicaux antérieurs sans importance clinique
, Problème léger: Problème actuel léger ou problème antérieur important
, Problème modéré: Atteinte ou morbidité modéré/e et/ou nécessitant un traitement
, Problème sévère: Pathologie sévère et/ou atteinte constante et invalidante et/ou maîtrise des problèmes chroniques difficile
, Problème très grave: Pathologie extrêmement sévère et/ou traitement immédiat requis et/ou défaillance d'un organe et /ou incapacité fonctionnelle grave
Overview of the MNA® -Its History and Challenges, J Nut Health Aging, vol.10, pp.456-465, 2006. ,
Screening for Undernutrition in Geriatric Practice: Developing the Short-Fom Mini Nutritional Assessment (MNA-SF), J. Geront, vol.56, pp.366-377, 2001. ,
The Mini-Nutritional Assessment (MNA®) Review of the Literature -What does it tell us?, J Nutr Health Aging, vol.10, pp.466-487, 2006. ,
, Revision 2006. N67200 12/99 10M Pour plus d'informations, 1994.